Publication:
Is There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?

dc.contributor.authorsInanc, Nevsun; Ozen, Gulsen; Yalcinkaya, Yasemin; Dalkilic, Ediz; Koca, Suleyman Serdar; Can, Gercek; Karatas, Ahmet; Pehlivan, Yavuz; Yazici, Ayten; Cefle, Ayse; Tufan, Abdurrahman; Akar, Servet; Senel, Soner; Oz, Burak; Akkoc, Nurullah; Onen, Fatos
dc.date.accessioned2022-03-10T17:56:32Z
dc.date.accessioned2026-01-11T09:11:27Z
dc.date.available2022-03-10T17:56:32Z
dc.date.issued2017
dc.identifier.doidoiWOS:000411824100541
dc.identifier.eissn2326-5205
dc.identifier.issn2326-5191
dc.identifier.urihttps://hdl.handle.net/11424/221992
dc.identifier.wosWOS:000411824100541
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofARTHRITIS & RHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleIs There Any Difference in RA Patients for Methotrexate Use Vs. Leflunomide Use As a Concomitant Treatment with Biological and Targeted Synthetic Dmards in Turkbio Registry?
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.titleARTHRITIS & RHEUMATOLOGY
oaire.citation.volume69

Files